Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · RetatrutideSupported
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
This is a major, GRADE-rated network meta-analysis — 262 RCTs, 99,791 participants, 19 drugs — and it puts both tracked peptides at the center of the obesity-pharmacotherapy map. With moderate-to-high certainty, tirzepatide showed the largest one-year weight loss (−14.9% vs lifestyle), with subcutaneous and oral semaglutide also substantial (−9.8% and −10.9%). Crucially, subcutaneous semaglutide was the only drug associated with reduced all-cause mortality and myocardial infarction, and both semaglutide and tirzepatide were associated with lower heart-failure risk — though the mortality/MI estimates are driven by cardiovascular-outcome trials in high-risk populations, an important scoping caveat. The analysis is admirably balanced on harms: larger weight loss generally came with more discontinuation and gastrointestinal events, and tirzepatide, while cutting fat mass most (−25.7%), also cut lean mass most (−8.3%) — a real signal on muscle loss. No drug meaningfully improved quality of life. This is high-quality synthesis and among the most useful single references for weighting these peptides. Read the benefit and harm columns together.
BMJ (Clinical research ed.)n=—HumanJul 8, 2026 - Study · RetatrutideWeak / none
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
This is a single animal study in a streptozotocin diabetic rat model, so findings are preliminary and not directly applicable to humans. Retatrutide was associated with partial attenuation of memory deficits and lower hippocampal TNF-alpha, though not full normalization. The authors note direct brain exposure was not established and call for further work.
Behavioural brain researchn=—AnimalJul 1, 2026 - Study · RetatrutideSupported
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
This meta-analysis pools randomized controlled trials, giving it relatively strong evidentiary weight for retatrutide's cardiometabolic effects. It reports consistent reductions in blood pressure and atherogenic lipids, with heterogeneity noted for cholesterol outcomes. Findings are association-based from a drug still under clinical development.
High blood pressure & cardiovascular preventionn=—HumanJun 29, 2026 - Study · RetatrutideSupported
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
A living systematic review and network meta-analysis for the American College of Physicians, and one of the strongest evidence syntheses in this batch: 69 randomised controlled trials, 112,511 participants, with 37 trials at low risk of bias. Network meta-analysis lets researchers rank treatments partly through indirect comparison, useful when head-to-head trials are scarce, but indirect estimates carry more uncertainty than direct ones. Researchers reported that nearly all drugs beat placebo or lifestyle intervention for weight loss while causing more adverse-event discontinuations; that semaglutide probably reduced mortality and major cardiovascular events; and that semaglutide and tirzepatide produced the greatest weight loss in both pairwise and network analyses. Crucially, the authors flagged that evidence for mortality, cardiovascular events and serious adverse events was limited and direct head-to-head data sparse, so the weight-loss ranking is far more certain than the hard-outcome claims. Weight this as high-quality comparative evidence for weight change, and more cautiously for survival and cardiovascular benefit.
Annals of internal medicinen=—HumanJun 16, 2026 - Study · RetatrutideSupported
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
This is a large phase 3 double-blind randomized controlled trial, the strongest tier of clinical evidence for retatrutide in type 2 diabetes. All three doses were associated with significantly greater HbA1c and weight reductions versus placebo, and the safety profile matched other GLP-1-class agents. Two deaths occurred, both reported as unrelated to the study drug; the trial was funded by the manufacturer.
Lancetn=—HumanJun 13, 2026 - Study · RetatrutideWeak / none
Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models.
This is a preclinical study in diet-induced obese mouse and hamster models, so results are early and not human data. Retatrutide was associated with marked weight loss, lower HOMA-IR, and reduced hepatic triglycerides, though it did not improve liver histopathology scores. The work primarily validates the models for testing obesity and MASH therapies.
Obesity (Silver Spring, Md.)n=—AnimalJun 1, 2026 - Study · RetatrutideWeak / none
GIPR:GCGR co-agonism restores normal weight in obese rodents.
This is preclinical rodent research where retatrutide serves as a benchmark comparator to a new GLP-1-sparing co-agonist. It offers a mechanistic signal that weight reduction can occur without GLP-1 activity, potentially reducing gastrointestinal effects, but findings are animal-only and early. Retatrutide is central to the comparison rather than the novel agent tested.
Molecular metabolismn=—AnimalJun 1, 2026 - Study · SemaglutideWeak / none
Do GLP-1 Receptor Agonists Sabotage Fat Grafts? A Scoping Review of GLP-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer.
This scoping review maps mechanistic reasons GLP-1-class drugs might interfere with autologous fat grafting, but the authors stress no clinical or preclinical studies have directly examined this outcome. The conclusions are explicitly hypothesis-generating rather than evidence-based. Retatrutide is mentioned partly in the context of off-label bodybuilding use.
Aesthetic surgery journaln=——Jun 1, 2026 - Study · RetatrutideMixed
Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease.
This paper reports the design and baseline characteristics of an ongoing mechanistic trial rather than any results. It establishes how retatrutide's effects on measured glomerular filtration rate and kidney structure will be evaluated, with outcomes still pending. Worth flagging as a trial to watch, with no efficacy data yet available.
Nephrology, dialysis, transplantationn=——May 29, 2026 - Study · RetatrutideSupported
Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes.
This is a pre-specified post-hoc metabolomic and lipidomic analysis drawn from two randomized, placebo-controlled phase 2 trials, so the underlying design is strong though the analysis is exploratory. Higher retatrutide doses were associated with biomarker shifts linked to fatty acid oxidation and lower insulin resistance. Findings are mechanistic and hypothesis-supporting rather than clinical endpoints.
The Journal of clinical endocrinology and metabolismn=—HumanMay 14, 2026 - Study · RetatrutideMixed
Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review.
This review consolidates phase 2 data with retatrutide as its central subject, making it a useful synthesis even though reviews sit below trials in the evidence hierarchy. It reports large reductions in weight, HbA1c, hepatic fat, and blood pressure alongside a dose-dependent increase in heart rate that clinicians must monitor. Figures come from phase 2 studies and await phase 3 confirmation.
Cardiology in reviewn=——May 11, 2026 - Study · RetatrutideWeak / none
Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair.
This is a single mechanistic study in a high-fat-diet mouse model using multi-omic profiling, so results are preliminary and not human data. Retatrutide was associated with suppressed lipogenesis, enhanced fatty acid oxidation, and reduced fibrotic and inflammatory signaling in white adipose tissue. The authors frame tissue-quality restoration as a hypothesis for further study.
Diabetology & metabolic syndromen=—AnimalApr 10, 2026 - Study · RetatrutideWeak / none
Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.
This animal study directly compares three tracked peptides in MC4R-knockout mice, a model of severe genetic obesity, so all three are central subjects. All reduced body weight and improved insulin, lipid, and liver markers, with tirzepatide showing the greatest effect. Findings are preclinical, and the authors note the model aligns with clinical observations.
International journal of obesity (2005)n=—AnimalApr 1, 2026 - Study · RetatrutideSupported
Retatrutide in type 2 diabetes mellitus and obesity: an overview.
This narrative overview is centered on retatrutide and consolidates trial findings across diabetes, obesity, and fatty liver outcomes. It reports strong associations with glycemic, weight, and hepatic fat improvements while flagging dose-dependent gastrointestinal effects. As a narrative review it summarizes rather than adds primary evidence.
Expert review of clinical pharmacologyn=——Apr 1, 2026 - Study · RetatrutideSupported
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.
A broad review of emerging GLP-1-based and multireceptor agents for obesity and diabetes. Several tracked peptides appear, including retatrutide, CagriSema (cagrilintide plus semaglutide), and tirzepatide as an established benchmark. Useful landscape context rather than primary data.
Endocrine reviewsn=——Mar 11, 2026 - Study · TirzepatideMixed
Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders.
A narrative overview of the mechanisms and clinical progress of multi-target incretin agonists. It covers tirzepatide and retatrutide as leading examples but breaks no new ground, noting open questions on safety, access, and long-term use. Suitable as background reading rather than primary evidence.
European journal of medicinal chemistryn=——Mar 5, 2026 - Study · RetatrutideSupported
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
This network meta-analysis of fourteen randomized controlled trials places it high in the evidence hierarchy for comparing glucagon receptor agonists. Retatrutide was associated with the largest weight and HbA1c reductions but ranked lower on tolerability than mazdutide. The authors call for head-to-head trials to confirm the indirect comparisons.
Endocrinology, diabetes & metabolismn=—HumanMar 1, 2026 - Study · TirzepatideSupported
Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.
This systematic review and meta-analysis pools ten randomized controlled trials with over three thousand participants, giving it strong evidentiary weight. The pooled incretin polyagonists, including tirzepatide and retatrutide, were associated with significant reductions in weight, waist circumference, HbA1c, and fasting glucose, but higher rates of gastrointestinal and hypoglycemic events. Serious adverse events did not differ significantly from placebo.
Cardiology in reviewn=—HumanFeb 19, 2026 - Study · SemaglutideSupported
Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials.
This network meta-analysis pools twelve randomized trials and reports a consistent heart-rate increase across the GLP-1 agonist class. The signal is a well-documented pharmacological effect rather than a new finding, and the analysis is limited by heterogeneity across the included trials. Useful context for the cardiovascular profile of these agents.
European journal of medical researchn=—HumanJan 26, 2026 - Study · RetatrutideMixed
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
This paper lays out the rationale and novel basket-trial design of the Phase 3 TRIUMPH program for retatrutide, spanning obesity, sleep apnea, and knee osteoarthritis. It reports study structure and endpoints rather than results, which are still to come. A significant registrational program worth tracking, with no efficacy data yet.
Diabetes, obesity & metabolismn=——Jan 1, 2026 - Study · RetatrutideMixed
IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes.
This IUPHAR review focuses on the mechanistic rationale for glucagon-receptor agonism in metabolic disease, with retatrutide cited as a leading triple agonist. The authors note that the evidence base is largely preclinical rodent data and that human confirmation remains limited. Valuable for mechanism context rather than clinical outcomes.
Pharmacological researchn=——Jan 1, 2026 - Study · RetatrutideMixed
The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities.
This perspective frames retatrutide as a significant advance in obesity pharmacotherapy, citing Phase 2 weight reductions and potential metabolic benefits. It is an opinion-oriented review rather than new trial data, and its framing is notably promotional, so it should be read with caution about tone. Included for the retatrutide narrative.
Clinical pharmacology in drug developmentn=——Jan 1, 2026 - Study · RetatrutideSupported
Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials.
This large Bayesian network meta-analysis pooled 102 randomised trials (98,693 people with type 2 diabetes) to compare 15 incretin-based therapies, including single, dual, and triple receptor agonists. Among tracked agents, tirzepatide and semaglutide ranked among the best for glycaemic control, and the authors reported that gastrointestinal adverse events were the most common and generally mild and transient, with low hypoglycaemia risk. Higher doses improved efficacy but increased side effects. The scale and low overall risk of bias make this a substantial synthesis, but network meta-analyses rest on indirect comparisons and SUCRA rankings that should not be over-interpreted as definitive head-to-head superiority. For semaglutide and tirzepatide readers, this reinforces their strong glycaemic positioning within the incretin class while underscoring the dose-tolerability trade-off. The authors call for long-term high-quality trials.
Frontiers in pharmacologyn=—HumanJan 1, 2026 - Study · RetatrutideWeak / none
GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists.
This is a narrative review of incretin-based therapies for adolescent obesity, spanning single (GLP-1RA), dual (tirzepatide), and triple (retatrutide) agonists. Its most concrete data point is from the STEP TEENS trial, where once-weekly semaglutide was associated with roughly 16% mean body-weight reduction over 68 weeks in adolescents; liraglutide produced more modest reductions. For tirzepatide and triple agonists, the authors are careful to note that paediatric data are limited or unavailable and that adult results were extrapolated cautiously. Gastrointestinal effects were the most common adverse events across agents. As a narrative (non-systematic) review, this synthesises rather than pools evidence and reflects author selection. The appropriately hedged bottom line: GLP-1RAs show clinically meaningful weight reduction in adolescents, but multi-receptor agonists need dedicated paediatric trials on long-term safety, development, and adherence before broader use. Weigh it as a balanced landscape overview, strongest where it cites STEP TEENS.
Diabetes, metabolic syndrome and obesity : targets and therapyn=——Jan 1, 2026 - Study · RetatrutideWeak / none
Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.
This qualitative exit-interview study captures patient-reported experiences from a Phase 2 retatrutide trial rather than clinical efficacy outcomes. Participants described reduced appetite, portion changes, and improved well-being, though a few reported social limitations or frustration. Useful for the lived-experience angle, with the caveat that self-reported perceptions from a small sample cannot establish efficacy.
Obesity pillarsn=——Dec 1, 2025 - Study · RetatrutideSupported
Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis.
This systematic review pools eight randomized trials and reports substantial glycemic and weight reductions with retatrutide in a comorbid CKD population, plus a signal toward reduced albuminuria. An interesting dose-response pattern is noted, with lower doses appearing more effective for glycemic control. Gastrointestinal tolerability is the main safety consideration.
Maedican=—HumanDec 1, 2025 - Study · SemaglutideSupported
Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review.
This review synthesizes twelve studies on gastrointestinal tolerability of anti-obesity drugs in non-diabetic adults, finding nausea, vomiting, diarrhea, and constipation most common with GLP-1 agonists during dose escalation. Symptoms were generally mild to moderate but can affect adherence. The authors note heterogeneity in study design as a limitation.
Medicina (Kaunas, Lithuania)n=—HumanNov 5, 2025 - Study · SemaglutideSupported
Weight management treatment in obesity.
A clinical review of obesity pharmacotherapy covering approved and investigational agents. Multiple tracked peptides appear, with reported weight-loss ranges of roughly 15 to 25 percent for the newer combinations and triple agonists. Landscape context rather than primary evidence.
Medicina clinican=——Nov 1, 2025 - Study · SemaglutideMixed
Medical Management of Obesity: A Comprehensive Review of FDA-Approved and Investigational Therapies.
This review surveys the obesity pharmacotherapy landscape, covering approved agents alongside investigational ones such as retatrutide. It summarizes efficacy, safety concerns, and patient-selection considerations without presenting new data. A reasonable orientation piece for readers new to the class.
Cureusn=——Nov 1, 2025 - Study · SemaglutideMixed
The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review.
This scoping review examines incretin mimetics as a possible option for insulin resistance in PCOS, reporting improvements in weight and insulin sensitivity across GLP-1, dual, and triple agonists. The evidence is early and heterogeneous, and the authors call for research into mechanisms and optimal use. A useful signal for an off-label application that warrants cautious framing.
Cureusn=——Sep 1, 2025 - Study · SemaglutideMixed
Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.
This review surveys the current and near-future GLP-1 landscape for obesity, discussing tolerability, access, and expanding indications. Semaglutide and tirzepatide are covered as approved agents with retatrutide among the pipeline drugs. A broad background piece with some forward-looking speculation.
Journal of obesityn=——Jun 1, 2025 - Study · RetatrutideWeak / none
Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado.
This is a market-surveillance study, not a clinical trial, and its relevance here is regulatory rather than about efficacy. Surveying 93 Colorado websites selling compounded GLP-1 products, researchers found semaglutide advertised by nearly all and tirzepatide by many, with a small number offering combination products; BPC-157 appeared in just one. The authors specifically flag that BPC-157 has been determined by the FDA to be unsafe for compounding, and that many sites made misleading regulatory claims (implying FDA approval, or calling products 'generic'). For readers, the takeaway is about the direct-to-consumer marketplace and its claims, not about whether any of these peptides work. Semaglutide and tirzepatide are FDA-approved prescription drugs with large trial evidence; the compounded and combination versions described here fall outside that approved evidence base.
Journal of pharmaceutical policy and practicen=——Jan 1, 2025